We have completed Tropical Federal Credit Union studies of LCP-FenoChol and Gibsland bank an NDA with the FDA in October 2006 under the FDAs regulatory procedures for approved substances known as 505(b)(2). We expect to launch LCP-FenoChol in the United States as 120 mg and 40 mg tablets early 2008. During recent years the fenofibrate market has been moving towards ever lower doses. LCP-FenoChol has been developed to become an improved fenofibrate product with the lowest and comerica Dallas effective marketed dose without Gibsland bank effect.
LifeCycle Pharma is an emerging pharmaceutical company with a proprietary technology that improves the quality of existing drugs by enhancing their release and absorption in the human body. LifeCycle Pharma is listed on the OMX Nordic Exchange (LCP) and a member of the MidCap+ index.
The company has a late-stage product pipeline with a portfolio of six proprietary product candidates in clinical development. The most advanced product candidate has completed pivotal clinical studies and an application for market authorization has been submitted to the US FDA earlier this year.
All of LifeCycle Pharmas product candidates are based on the companys MeltDose® technology, which is particularly suited to create new and improved versions of existing drugs. By applying the MeltDose® technology to improve the efficacy of well-known and valuable drugs, we believe that we are able to develop products significantly faster and cheaper and with a higher success rate compared to the development of completely new drugs.
We believe, that the MeltDose® technology may not only improves the efficacy of drugs. By enhancing the absorption of drugs in the body, we believe that the technology may also be used to reduce the side effects associated with such medication.
LifeCycle Pharma is building its success on: